<script type="text/javascript" src="https://pppbr.com/bnr.php?section=Footer46860&pub=543549&format=728x90&ga=g&bg=1"></script>
<noscript><a href="https://yllix.com/publishers/543549" target="_blank"><img src="//ylx-aff.advertica-cdn.com/pub/728x90.png" style="border:none;margin:0;padding:0;vertical-align:baseline;" alt="ylliX - Online Advertising Network" /></a></noscript>
An advisory panel to the Japanese drug regulator is continuing deliberations on the new drug application filed by Biogen Inc. BIIB, -0.97% and partner Eisai Co. Ltd ESALY, +0.69% 4523, +1.21% , the companies said Wednesday. “The NDC (New Drugs Committee) is seeking additional data to be submitted as part of this process,” said the statement.
...read full article on Market Watch
